HC Wainwright targets Emergent BioSolutions stock at USD 10.00

Published on 10/20/2026 at 19:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due November 2, 2026. Emergent BioSolutions stock costs EUR 5.54 on October 20, 2026 at 7:31 p.m. CEST.

Analyst target and reporting date

HC Wainwright set a USD 10.00 target for Emergent BioSolutions on September 9, 2026.
Third-quarter 2026 results are scheduled for November 2, 2026.
Emergent BioSolutions stock costs EUR 5.54 at Lang & Schwarz on October 20, 2026 at 7:31 p.m. CEST.

EBS, US29089Q1058, Illustration mit AI erstellt.

Emergent BioSolutions (ISIN US29089Q1058) remains anchored by a USD 10.00 analyst target ahead of its next results. MarketBeat reported on October 5, 2026 that HC Wainwright had reaffirmed its buy rating and issued the target on September 9, 2026. The stock was trading at EUR 5.54 at Lang & Schwarz on October 20, 2026 at 7:31 p.m. CEST.

Results arrive November 2

Emergent BioSolutions will discuss third-quarter 2026 results on November 2, 2026, after the company announced the date on October 15, 2026. The conference call is scheduled for 5:00 p.m. eastern time, according to the company's investor-relations release.

The date gives investors a defined checkpoint after a sharp second-quarter revenue increase and a weaker full-year outlook. The next report will show whether government-related demand can offset pressure in the commercial naloxone business.

Second-quarter revenue reached USD 234.30 million

For the second quarter of 2026, revenue reached USD 234.30 million, compared with a USD 177.50 million consensus estimate, while adjusted earnings per share reached USD 0.60 versus an expected loss of USD 0.08, MarketBeat reported on October 5, 2026.

The same report said six analysts carried a consensus Hold rating and an average USD 10.00 target. That target stands 60.77 percent above the NYSE price of USD 6.22 at 1:36 p.m. EDT on October 20, 2026, based on the latest quoted figures.

What will the next report clarify?

The key issue is the balance between medical countermeasure demand and commercial products. Emergent's investor-relations page describes a portfolio spanning smallpox, mpox, botulism, Ebola, anthrax and opioid overdose products. The company also provides manufacturing and development services for public-health products.

At Lang & Schwarz, the euro quotation provides the German-market view while the NYSE quotation remains the primary-market reference. The stock's USD 4.36 to USD 14.06 52-week range and USD 318.9 million market capitalization were listed for October 20, 2026.

Price and reporting date

The November 2 results date is the next concrete event for the stock. The USD 10.00 target and the USD 6.22 NYSE quotation leave the November report as the next test of whether the strong second-quarter revenue figure can be repeated.

Emergent BioSolutions stock was trading at EUR 5.54 at Lang & Schwarz on October 20, 2026 at 7:31 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Emergent BioSolutions stock.